Document is current
Any future updates will be listed below
-
Authors
De Geronimo, Daniele
Parravano, Mariacristina https://orcid.org/0000-0002-2223-7311
Sacconi, Riccardo
Fragiotta, Serena
Giannini, Daniela
Costanzo, Eliana
Varano, Monica
Querques, Giuseppe
- License Information
-
More Information
Article History
Received: 16 November 2023
Accepted: 16 December 2023
First Online: 1 February 2024
Declarations
:
: The authors declare that they have no conflict of interest.
: Observational case-series performed at IRCCS-Fondazione Bietti in Rome, Italy, including treatment-naïve PDR eyes, without macular edema, treated with three monthly 2.0 mg intravitreal injections of aflibercept, between January and December 2021. The study received Institutional Review Board approval and followed the tenets of the Declaration of Helsinki.
: After signing informed consent, all patients underwent a complete ophthalmological examination and multimodal imaging at baseline (T0) and 1 month after the third injection (T1) consisting of: UWF-CFPs and UWF-FA (Optos California; Optos, PLC, Dunfermline, Scotland) and SS-WF-OCTA (PlexElite OCTA, Carl Zeiss Meditec, Inc., Dublin, CA, USA).
